Capricor Announces Positive One-Year Results from HOPE-2 Open Label Extension Study Evaluating CAP-1002
Dr. Linda Marbán, CEO of Capricor Therapeutics, presented a Late-Breaking News session at PPMD’s 2022 Annual Conference, announcing positive 1-year efficacy results from the ongoing HOPE-2 open label extension study of CAP-1002 in non-ambulant Duchenne…Learn More